Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $98
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on Boston Scientific and raised the price target from $88 to $98, indicating confidence in the company's future performance.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has maintained a Buy rating on Boston Scientific and increased the price target from $88 to $98, suggesting a positive outlook for the company's stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates a strong belief in Boston Scientific's potential for growth. This is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100